Oculis Holding AG (OCS) Cash from Operations (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Cash from Operations came in at 19585420.81 in Q1 2026, up 7.14% year-on-year from 18280015.07 in Q1 2025, and up 6.16% quarter-over-quarter from 20870763.3 in Q4 2025.
Oculis Holding AG (OCS) Cash from Operations (2022 - 2026) Analysis & Trends
Oculis Holding AG's Cash from Operations history runs 5 years deep, the most recent figure standing at 19585420.81 for Q1 2026.
- On a quarterly basis, Cash from Operations rose 7.14% year-over-year to 19585420.81 in Q1 2026; TTM through Mar 2026 was 78056596.89, a 28.13% decrease from a year earlier, with the FY2025 full-year figure at 79971143.7, down 43.82% from the prior year.
- Cash from Operations grew to 19585420.81 in Q1 2026 per OCS's latest filing, from 20870763.3 in the prior quarter.
- Across five years, Cash from Operations topped out at 6781397.15 in Q4 2022 and bottomed at 21091606.91 in Q1 2025.
- The 5-year median for Cash from Operations is 15718761.35 (2024), against an average of 15322007.63.
- Across the five-year window, Cash from Operations sank 136.21% in 2023 and grew 24.15% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 6781397.15 in 2022, then sank by 136.21% to 16018579.72 in 2023, then advanced by 24.15% to 12150358.55 in 2024, then plunged by 71.77% to 20870763.3 in 2025, then increased by 6.16% to 19585420.81 in 2026.
- Per Business Quant, the three latest OCS Cash from Operations figures stand at 19585420.81 (Q1 2026), 20870763.3 (Q4 2025), and 16773969.47 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 70.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.59 Mn |
| Mar 31, 2026 | -19.59 Mn |
| Dec 31, 2025 | -20.87 Mn |
| Dec 31, 2025 | -20.87 Mn |
| Sep 30, 2025 | -16.77 Mn |
| Sep 30, 2025 | -16.77 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Mar 31, 2025 | -21.09 Mn |
| Mar 31, 2025 | -21.09 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Sep 30, 2024 | -12.48 Mn |
| Sep 30, 2024 | -12.48 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Dec 31, 2023 | -16.02 Mn |
| Dec 31, 2023 | -16.02 Mn |